Usefulness of preoperative FDG-PET for detection of gastric cancer

Mukai, Kota; Ishida, Yasuhiko; Okajima, Kunio; Isozaki, Hiroshi; Morimoto, Tsukasa; Nishiyama, Shoji

doi:10.1007/s10120-006-0374-7

Cited by 148 publications

(132 citation statements)

References 11 publications

(21 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported lower FDG uptake in the diffuse type than in the intestinal type according to the Lauren classification [20,29,30]. Although a few studies have reported no significant differences because of different study populations compared with those in the present study, the FDG uptake and detection rate of the diffuse type were lower than those of the intestinal type [31,32]. In accordance with the previous studies, the present study showed that the diffuse type had lower FDG uptake than the intestinal type.…”

Section: Discussionsupporting

confidence: 88%

“…Tian et al [29] found a positive correlation between the FDG uptake and tumor size in early and advanced gastric adenocarcinomas. Mukai et al [32] reported that the detection rate of small-sized tumors was significantly lower than that of large-sized tumors. In these studies, the patients with early gastric cancer who had small-sized tumors were included for the evaluation of FDG uptake.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation of Primary Tumor FDG Uptake with Histopathologic Features of Advanced Gastric Cancer

Kim

Won

Song

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Histopathologic features could affect the FDG uptake of primary gastric cancer and detection rate on FDG PET/CT. The aim of this study was to evaluate the FDG uptake of primary gastric cancer by correlating it with the histopathologic features of the tumors. Methods Fifty patients with locally advanced gastric adenocarcinoma who were referred for preoperative FDG-PET/CT scans were enrolled in this study. The detection rate of PET/ CT and maximum standardized uptake values (SUV max ) of the primary tumor were compared using the WHO, Lauren, Ming and Borrmann classifications and tumor size and location. Results In 45 of the 50 patients (90 %), the primary gastric tumors were detected by FDG PET/CT. On comparison using the WHO classification, the detection rate and SUV max of the tubular type were significantly higher than those of the poorly cohesive type. On comparison using the Lauren and Ming classifications, the SUV max s of the intestinal type and expanding type were significantly higher than those of the diffuse and infiltrative type, respectively. On comparison using the Borrmann classification and tumor size and location, there was no significant difference in the detection rate and SUV max of primary gastric tumors. Conclusion This study demonstrates that the poorly cohesive type according to the WHO classification, diffuse type according to the Lauren classification and infiltrative type according to the Ming classification have low FDG uptake in patients with locally advanced gastric carcinoma. Understanding the relationship between primary tumor FDG uptake and histopathologic features would be helpful in detecting the primary tumor by FDG PET/CT in patients with gastric cancer.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Correlation of Primary Tumor FDG Uptake with Histopathologic Features of Advanced Gastric Cancer

Kim

Won

Song

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Even for advanced tumors, detection rates have been reported to range from 34 to 94% [18][19][20]. These studies found a significant association between FDG uptake and the depth of tumor invasion and tumor size.…”

Section: Depth Of Tumormentioning

confidence: 92%

“…Regarding the detection of lymph node involvement in patients with T1 tumors, Mukai et al [20] assessed FDG uptake in 27 patients with T1 tumors and found that 7 (26%) patients were PET-positive and 20 patients were PET-negative. Two of the 7 PET-positive patients had nodal involvement, and the primary tumors of both patients were the intestinal type.…”

Section: Depth Of Tumormentioning

confidence: 99%

Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature

et al. 2011

View full text Add to dashboard Cite

Since April 2010, the Japanese Public Health Insurance System has covered the costs incurred for performing 18 F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) imaging for patients with advanced gastric cancer. The aim of this review was to evaluate the clinical impact of PET for patients with gastric cancer. A systematic literature search was performed in PubMed/MEDLINE using the keywords ''gastric cancer'' and ''PET'' to search for relevant articles published from January 2000 to September 2010. The clinical impact of selected articles was assessed by the authors to evaluate the following: (a) tumor staging, (b) diagnosis for recurrent disease, (c) evaluation of treatment response, and (d) screening for gastric cancer. FDG uptake increases in papillary adenocarcinoma, tubular adenocarcinoma, and solid-type poorly differentiated adenocarcinoma. This uptake is also associated with glucose transporter 1 expression. The sensitivity and specificity of FDG-PET for metastatic lymph node detection were 21-40% and 89-100%, respectively. The sensitivity and specificity for distant metastasis detection were 35-74% and 74-99%, respectively. Treatment response can be detectable at an earlier stage by PET than by computed tomography (CT), because FDG uptake by cancer cells decreases according to the treatment response. In summary, although PET has limitations such as frequent false-negative cases in signetring cell carcinoma and non-solid type poorly differentiated carcinoma, it can contribute to the selection of a more appropriate treatment modality by detecting distant metastases and treatment response.

show abstract

“…37,38 Because of this high level of specificity and tumor responsiveness to therapy, early response detection also has been described. 39,40 In this study, after a decrease in FDG uptake by 35% or more and assessment after 14 days of therapy, histopathologic response after 3 months of therapy was identified correctly in 77% of the patients.…”

Section: Gastric Cancermentioning

confidence: 99%

PET Imaging for Treatment Response in Cancer

Eary

2008

PET Clinics

View full text Add to dashboard Cite

KeywordsPET; FDG; Cancer imaging; Response imaging PET tumor surveys have become widely used in clinical practice. [F-18] fluorodeoxyglucose (FDG) is the most commonly used radiotracer for clinical indication of tumor staging and restaging after treatment. FDG PET consistently has exhibited better diagnostic performance than conventional imaging in adults and pediatric populations. [1][2][3][4] More recently, a growing body of literature is reporting the use of FDG and other PET imaging agents in treatment response assessment. [5][6][7] In many cases, FDG PET has proved to be a reliable means of noninvasively observing response in various treatments.Additionally, reliable determination of past treatment changes, including recurrent tumors and differentiation of benign and malignant lesions, will reduce morbidity and the cost of care in anatomic imaging. The Response Evaluation Criteria in Solid Tumors (RECIST) are a useful means to report quantitative changes in tumor size on CT scans in many different tumors in response to treatment. 8,9,10 Many tumor types, however, do not change size appreciably in response to treatment. Early changes that may indicate treatment regimen effectiveness also may not result in tumor change in size. FDG PET is a relatively sensitive indicator of treatment response in many tumors, indicating changes in metabolism that often precede or take the place of tumor size change. Fig. 1 shows some examples of FDG PET tumor response.Recently, several cooperative groups have addressed the use of FDG PET as a biomarker for cancer treatment response. An early report by the European Organization for Research and Treatment of Cancer (EORTC) set criteria for treatment response according to changes in tumor FDG uptake compared to baseline. 2 These criteria include:Complete response (CR)- [F-18] fluorodeoxyglucose uptake is comparable to baseline activity in all lesions Partial response (PR)-all target lesions have greater than 25% decrease in standardized uptake variable (SUV) Stable disease (SD)-target lesions have less than 25% increase or decrease in SUV Progressive disease (PD)-at least one target lesion has greater than 25% increase in SUV, or new lesions appear (regardless of SUV changes in target lesions)These criteria are in wide use today for clinical FDG PET imaging. A set of criteria for clinically significant changes in tumor FDG uptake, however, is based on consistent parameters for the FDG PET acquisition between studies in the same patient, and between patient imaging groups at different institutions. Development and evaluation of new cancer therapies could be enhanced by a set of validated biomarkers for treatment response. FDG PET meets these criteria in clinical studies, if imaging studies are conducted with patients on clinical therapeutic trials in a reliable and consistent manner. 3 To address the consistency in FDG PET data for use as NIH Public Access A review of cancer treatment response begins with consideration of the pathological basis of the tumor process. Tumors are c...

show abstract

Usefulness of preoperative FDG-PET for detection of gastric cancer

Cited by 148 publications

References 11 publications

Correlation of Primary Tumor FDG Uptake with Histopathologic Features of Advanced Gastric Cancer

Correlation of Primary Tumor FDG Uptake with Histopathologic Features of Advanced Gastric Cancer

Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature

PET Imaging for Treatment Response in Cancer

Contact Info

Product

Resources

About